Background Mechanical autotransfusion systems for washed shed blood (WSB) were introduced to reduce the need for postoperative allogenic blood transfusions (ABTs). Although some authors have postulated decreased requirements for ABT by using autologous retransfusion devices, other trials, mostly evaluating retransfusion devices for unwashed shed blood (USB), verified a small or no benefit in reducing the need for postoperative ABT. Because of these contradictory findings it is still unclear whether autologous retransfusion systems for WSB can reduce transfusion requirements. Questions/purposes We therefore asked whether one such autologous transfusion system for WSB can reduce the requirements for postoperative ABT. Methods In a prospective, randomized, controlled study, we enrolled 151 patients undergoing TKA. In Group A (n = 76 patients), the autotransfusion system was used for a total of 6 hours (intraoperatively and postoperatively) and the WSB was retransfused after processing. In Control Group B (n = 75 patients), a regular drain without suction was used. We used signs of anemia and/or a hemoglobin value less than 8 g/dL as indications for transfusion. If necessary, we administered one or two units of allogenic blood. Results Twenty-three patients (33%) in Group A, who received an average of 283 mL (range, 160-406 mL) of salvaged blood, needed a mean of 2.1 units of allogenic blood, compared with 23 patients (33%) in Control Group B who needed a mean of 2.1 units of allogenic blood. Conclusions We found the use of an autotransfusion system did not reduce the rate of postoperative ABTs. Level of Evidence Level II, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.
Introduction
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Although the use of retransfusion systems is becoming more common in the orthopaedic community [15, 16, 37, 42] , it remains unclear whether they reduce the requirement for ABTs. Although some authors [3, 6, 25] have found good-quality drainage blood with a hematocrit of 75% to 88% directly after collection, other studies [1, 14, 19, 31] could not verify a reduction in the requirements for postoperative ABTs by using these systems. However, it is difficult to compare the results of the different studies of retransfusion systems because of differences in techniques for processing shed blood (filtering, washing, and anticoagulation), criteria for transfusion, levels of evidence, and methods for determining blood loss.
In general, retransfusion devices can be divided in two major groups: systems for unwashed shed blood (USB) and systems for washed shed blood (WSB) [21, 23] . Owing to the higher related risk of a transfusion reaction to USB (compared with WSB), some authors [12, 35, 39, 40] advise washing the shed blood before retransfusion.
Because of lack of literature regarding WSB and contradictory results, there is no clear consensus regarding the utility of autotransfusion systems and its economic and clinical benefits to decrease the need for ABTs. Therefore, we performed a randomized, prospective, controlled trial comparing patients treated with an autologous transfusion system for WSB with a control group treated only with a regular drain without suction after TKA.
We determined (1) whether the use of an autologous transfusion system with WSB can reduce requirements for postoperative ABTs; (2) the effect of retransfused WSB on hemoglobin level by measuring hemoglobin values after WSB donation; and (3) whether there is a decreased postoperative infection rate with the use of an autologous transfusion system as postulated by del Trujillo et al. [7] . Our intention was to determine whether it is possible to reduce the need for postoperative ABTs and to lower the early postoperative infection rate.
Patients and Methods
We conducted a prospective, controlled, randomized study that included 151 patients treated with primary elective TKA for osteoarthritis from December 2007 to January 2009. During the study period, we treated a total of 223 patients with TKAs. For this study we included patients with primary osteoarthritis of the knee treated with primary nonconstraining TKA prostheses. We excluded 72 patients for the following reasons: (1) unwillingness to participate in the study (n = 53) and (2) revision arthroplasty (n = 19). The remaining 151 patients were randomized into two groups: Group A, in which the Orthopedic Perioperative Autotransfusion System (OrthoPAT 1 , Haemonetics Corp, Braintree, MA, USA) was used for intraoperative and postoperative blood salvage and retransfusions (n = 76 patients, 76 TKAs), and Control Group B, in which no retransfusion system was used (n = 75 patients, 75 TKAs). Randomization was accomplished by a blinded method performed by an independent secretary in the hospital's administration office. Sealed envelopes were generated including an assigned patient code separating patients into two groups. Patients with even-numbered codes were allocated to Group A using OrthoPAT 1 for intraoperative and postoperative blood salvage and retransfusion. Patients with odd-numbered codes were assigned to Control Group B without using a retransfusion system. The envelopes were opened preoperatively in the operating room shortly before beginning surgery.
Because of missing data, the results of only 140 of the 151 patients were available: 70 patients (70 TKAs) in Group A and 70 patients (70 TKAs) in Control Group B. Six patients in Group A and five in Control Group B were removed from the study owing to (1) lack of data (six patients), (2) technical problems with the retransfusion system (four patients), and (3) acute intraoperative renal failure (one patient). We had prior approval of our institutional review board.
According to a preliminary power analysis that was based on a pilot study in our orthopaedic department, which included 40 patients (20 patients [20 TKAs] treated with OrthoPAT 1 versus 20 patients [20 TKAs] with no autologous retransfusion system), we found the proportions of 0.35 and 0.60 for ABT rate. A two-group Fisher's exact test with a two-sided significance level of 0.05 had a power of 80% to detect a difference between the proportions 0.35 and 0.60 when the sample size in each group will be 70 patients. Owing to this a priori power analysis a difference of more than 17 ABTs would make a statistical difference.
We recorded demographic data, medical history (coronary artery disease, use of anticoagulants, and American Society of Anesthesiologists [ASA] classification [13] ), preoperative and postoperative hemoglobin levels, duration of surgery, need for ABT, amount of retransfused WSB, and early complications (including allergic reactions, wound infections, minor and major bleeding, deep venous thrombosis, nerve injuries, pulmonary embolism) at the preoperative examination and during the hospital stay.
Preoperative data for cardiopathy, angiopathy, preoperative anemia, and anticoagulant treatment, demographic data (age, BMI, sex, ASA score), and mean duration of surgery showed no differences between Group A and Control Group B (Table 1) . Preoperative anticoagulant and antiinflammatory medications were stopped 10 days before surgery. All patients received antithrombotic prophylaxis with 40 mg low-molecular-weight heparin 1 day before surgery and for 42 days postoperatively. If preexisting oral anticoagulation was necessary, treatment was changed to a standardized subcutaneous regime of low-molecularweight heparin in therapeutic dosage.
All patients underwent a primary elective TKA without the use of an intraoperative tourniquet using a medial parapatellar surgical approach. The surgeries were performed in the same operating theaters with cemented, posterior-stabilized total knee prostheses with a rotating polyethylene inlay (NexGen 1 LPS-Flex Mobile; Zimmer, Inc, Warsaw, IN, USA) and a standardized postoperative rehabilitation regimen. The surgical procedures and anesthesia techniques were identical in both groups. Anesthesia technique (spinal or general) was selected according to preference and general state of the patient. Each patient received an intravenous perioperative infection prophylaxis of 1500 mg cefuroxime.
For postoperative pain management, patients of both groups received femoral nerve catheters with continuous infusions of ropivacaine (0.2%, 6 mL/hour) and single injections of ropivacaine (0.2%, 20 mL) via sciatic nerve catheters, if required. Starting at 72 postoperative hours, the pain was managed using NSAIDs and opiates, and the femoral and sciatic nerve pain catheters were removed.
In this study, we used a retransfusion system that processed the collected blood by completing anticoagulation, filtering, washing, and centrifugation steps. In Group A, the autotransfusion system was used for 6 hours total after skin incision (intraoperatively and postoperatively). Intraoperatively, the autotransfusion system was used with a negative pressure of 100 mm Hg; postoperatively, the pressure was at 50 mm Hg. The WSB was anticoagulated, filtered, washed with saline, and centrifuged to separate waste products. After retransfusion of the WSB, Group A continued with a closed drainage system without suction, similar to Control Group B for the same total of 48 hours postoperatively.
Postoperatively the patients were maintained at bedrest with continuous passive motion on the first postoperative day. Physical therapy was started on the second postoperative day twice a day for 45 minutes until the tenth postoperative day. Active exercise therapy with a walking assist three times a day and supervised autonomous training to improve ROM was added on the third postoperative day. After hospital treatment, all patients were transferred to a stationary rehabilitation facility for 3 more weeks. All patients were mobilized with a pair of full-weightbearing crutches for 6 weeks postoperatively.
The indications for transfusion were signs of anemia (vertigo, nausea, vomiting, hypotension [systolic blood pressure \ 100 mm Hg], tachycardia [[ 100 beats/minute]) or a hemoglobin level less than 8 g/dL. Hemoglobin levels were determined preoperatively, 2 hours after application of WSB, and on Postoperative Days 3 and 5 or if signs of anemia led to the need for ABT. At each administration of ABT, hemoglobin levels were recorded; patients with missing documentation were eliminated from the study.
To compare demographic and clinical data between the two groups, we performed several statistical tests. We determined differences in need for ABTs, sex, occurrence of cardiopathy/angiopathy, and need for preoperative anticoagulants using Fisher's exact test. The t-test was used for evaluation of hemoglobin values, age, BMI, and surgery time. The Mann-Whitney U test was used for evaluation of the ASA score. We used SPSS 1 software (SPSS Version 19; SPSS Inc, Chicago, IL, USA) for statistical analyses.
Results
We found no difference (p = 0.999) in the need for ABT between the two groups: 23 of 70 patients (33%) in Group A received ABT versus 23 of 70 patients (33%) in Control Group B ( Table 2 ). All of the allogenic blood units were transfused between Postoperative Days 2 and 5. The mean hemoglobin value at the time of ABT was not different (p = 0.799) between the two groups ( Table 2 ). In Group A, patients received a mean of 283 ± 122.6 mL WSB. The hemoglobin values of Group A, versus the values of Control Group B, tended to be higher (p = 0.062) 2 hours after the donation of the WSB but then decreased by Postoperative Days 3 (p = 0.221) and 5 (p = 0.132) ( Fig. 1) . We found no difference (p = 0.585) in the postoperative blood loss by Redon drainage between the two groups.
In one patient, we observed immediate hypotension, vomiting, and pyrexia after transfusion of the WSB. However, during the hospital stay (range, 9-14 postoperative days), we found no differences in early postoperative complications (allergic reactions, wound infections, deep venous thrombosis, minor and major bleeding, neural deficiencies, arterial embolism) or the number of erythrocyte units used in this patient because of acute anemia ( Table 2) .
Discussion
Orthopaedic surgeries, especially TKAs, frequently are associated with substantial perioperative and postoperative blood loss. Consequently, postoperative blood transfusions are common [9] . However, because of the well-documented risks of ABTs, such as transfusion-associated infections or immunomodulatory effects [2] , a reduction in the use of ABT would be a great improvement. Although some authors reported the use of autologous retransfusion systems as a good opportunity to reduce perioperative blood loss [5, 26, 34, 36] , there is no consensus regarding whether retransfusion systems also can reduce the use of postoperative ABTs. Therefore, we determined (1) whether the use of an autologous transfusion system with WSB can reduce requirements for postoperative ABTs; (2) the effect of retransfused WSB on hemoglobin level by measuring hemoglobin values after WSB donation; and (3) whether there is a decreased postoperative infection rate with the use of an autologous transfusion system as postulated by del Trujillo et al. [7] .
Despite a prospective, randomized, controlled study design, this trial is restricted by some limitations. First, we could only use the results of 140 patients because of the exclusion criteria and incomplete documentation of the data. Second, we did not determine blood loss and the additional blood loss owing to the vacuum activity of the OrthoPAT 1 was not included in this evaluation. An accurate measurement of intraoperative blood loss is time intensive and needs the complex cooperation of different departments (orthopaedic surgeons, anesthetists, and nursing staff), which was not possible in our setting.
We found no benefit in using OrthoPAT 1 as a retransfusion system for WSB. Our results verified no reduction in the need for postoperative ABT by using OrthoPAT 1 as a retransfusion device for WSB. This is in contrast to some studies [7, 11, 20, 22, 24, 34] reporting a decreased requirement for ABT with a lower risk of transfusionassociated complications and economic benefit using one of several autologous retransfusion devices (OrthoPAT 1 ; ABT Trans 1 [Surgical Innovations Ltd, Leeds, UK] , Bellovac ABT 1 [AstraTech AB, Mölndal, Sweden]). In contradiction to our data, del Trujillo et al. postulated a lower ABT rate for patients undergoing THAs who were treated with the OrthoPAT 1 retransfusion device [7] . However, because we evaluated the OrthoPAT 1 for TKA a direct comparison with our results is difficult. Moonen et al. [20] reported a lower ABT rate in the retransfused group using the Bellovac ABT 1 for THAs and TKAs. This contrasts with the report of Amin et al. [1] , who found no benefit of using Bellovac ABT 1 for only TKAs. Grosvenor et al. [11] , Munoz et al. [22] , and Smith et al. [34] suggested a decreased ABT rate for patients treated with autologous retransfusion systems. However, these studies Evaluation of an Autologous Transfusion System 1323 used different retransfusion devices for TKAs and THAs. Therefore a reliable comparison with our results is not possible ( Table 3 ). In addition, the retrospective study design [11] , the comparison of a prospective study group with a retrospective control group [22] , or the missing randomization procedure in a prospective published trial [7] , all postulating a lower ABT rate for the reinfusion group, are critical limitations and therefore not directly comparable to our prospective, randomized study. Some previous studies that have noted only a small or no benefit in reducing the need for postoperative ABT evaluated a retransfusion device for USB [17, 18, 23, 30] . Even when trials reported a lower ABT rate for the autologous retransfusion group, they either found no difference in administered ABT units per patient [7, 20, 34] or the ABT number per patient transfused was not analyzed [11, 22, 34] (Table 3 ). We believe patient blood management of individual patients would be more likely to reduce the number of administered ABT units in the retransfused and control groups than using an autologous retransfusion device. The vacuum activity of the retransfusion device caused additional blood loss, which could explain the absence of any benefit of the retransfusion system [18] .
The hemoglobin values tended to be higher in Group A 2 hours after WSB donation, which was not the case in the subsequent determinations on the third and fifth postoperative days. Although several articles have suggested a high hematocrit level of collected drainage blood [3, 6, 25] , use of WSB did not result in a substantially higher hemoglobin value in the reinfusion group at all measurement points. The same conclusions have been proposed by others [1, 7, 20, 22] , suggesting a small and insignificant elevation of the hemoglobin value after autologous blood retransfusion 3 to 4 days postoperatively. Smith et al. [34] measured hemoglobin values immediately after surgery. Grosvenor et al. [11] provided no postoperative hemoglobin levels for the reinfusion and control groups. Therefore a reliable comparison to our results was not possible (Table 3) . However, our findings were similar to those in the literature since all published studies reporting preoperative hemoglobin levels between the retransfusion and control groups found no differences [1, 7, 20, 22, 34] (Table 3) .
Although we found no differences in postoperative complications and occurrence of transfusion reactions between our two groups, del Trujillo et al. [7] reported a trend toward lower postoperative infection rates for patients treated with the OrthoPAT 1 autologous retransfusion system. However, we can confirm there is no higher incidence of early postoperative infections and the Ortho-PAT 1 device is easy to use. Although we have used this device for several years, technical problems have occurred in just two patients during the study period, during which the autologous transfusion system was out of order.
Comparison of our results with those of other trials is difficult owing to the use of different autologous transfusion systems for TKAs and THAs. Our study is the only trial evaluating the OrthoPAT 1 for TKA. We found no differences in reducing the number of required ABTs or hemoglobin levels during followup. In one patient, we observed an allergic reaction during retransfusion of the WSB. The cost savings achieved by eliminating the autotransfusion system can be used to enhance the patient's individual blood management as a key way to reduce blood transfusions [32, 38] . As a result of our findings, we now collect blood 8 weeks before the operation to determine the hemoglobin value and, if necessary, correct it (intravenous iron, erythropoietin). Additionally, intraoperatively we administer a single shot of tranexamic acid (if there is no contraindication) and check hemoglobin levels 6 hours postoperatively. If the levels are lower than 9.5 g/dL, they are monitored daily; otherwise, they are checked on Postoperative Days 3 and 5 or at any sign of anemia. If the hemoglobin level is lower than 8 g/dL, we try to limit the number of allogenic blood units by administering only one, in accordance with the clinical state and medical history. It is also our intention to reduce the need for ABTs by improving individual blood management for each patient [4, 27] and to find a more exact personal limit of the hemoglobin level.
